You choose, we deliver
If you are interested in this story, you might be interested in others from The Journal Gazette. Go to and pick the subjects you care most about. We'll deliver your customized daily news report at 3 a.m. Fort Wayne time, right to your email.


  • Black Friday gun buys test background check system
    BRIDGEPORT, W.Va. (AP) — Black Friday isn't just when shoppers rush to stores for holiday sales. It's also one of the busiest days of the year for gun purchases.
  • Ferguson demonstrators rally across US for second day
    People protesting the Ferguson, Missouri, grand jury decision took to the streets in cities across the U.S. for a second day Tuesday, showing that the racially charged case has inflamed tensions thousands of miles from the predominantly black St.
  • 2 men charged with trying to support Islamic State
    MINNEAPOLIS – One of two Minnesota men accused of planning to join the Islamic State group was stopped at an airport by FBI agents before traveling to the Middle East, but the other man slipped by authorities, according to a criminal complaint

Groups push wider use of brain scans

Insurers urged to expand coverage with Alzheimer’s

Advanced imaging that detects plaque in the brain should be covered by Medicare and private insurers for select people with dementia to help diagnose or rule out Alzheimer’s disease, advocates and doctors said.

The recommendations released Monday are the first to help govern the burgeoning field of brain imaging and may increase the use of the practice to improve care for the 5 million Americans affected with Alzheimer’s.

The Alzheimer’s Association and the Society of Nuclear Medicine and Molecular Imaging crafted the proposal to address which patients might benefit from the PET scan technology that detects the plaque.

While amyloid plaque is a hallmark of Alzheimer’s disease, not everyone with it has the mind-robbing condition. PET scans require a drug injected into patients to highlight the plaque for doctors. Eli Lilly & Co.’s Amyvid is the only compound currently approved for use with PET scans for this purpose.

“This is going to become much more ubiquitous and available over the next few years,” said Maria Carrillo, vice president of medical and scientific relations at the Chicago-based Alzheimer’s Association. “It’s something physicians can refer their patients for if they need additional information.”

Lilly’s drug isn’t now covered by Medicare, the U.S. insurance program for the older adults and those with disabilities.

Products from General Electric, Piramal Enterprises Navidea Biopharmaceuticals are expected to reach the market in the next two years.

The costs of the scans vary depending on where they are done and who conducts them, though prices for standard PET imaging range from $1,000 to $3,000.

Alzheimer’s is the sixth-leading cause of death in the U.S., according to the Alzheimer’s Association.

The number of people with the disease is expected to double within 20 years as the world’s population ages, to as many as 65.7 million people in 2030 and 115 million by 2050, the Geneva-based World Health Organization said last April.

There is no treatment to cure or slow the disease. Current therapies address only symptoms.

While Alzheimer’s is the most common cause of dementia in the aged, memory problems may also stem from drug side effects, strokes, thyroid problems and vitamin deficiencies.

The guidelines identify three groups of patients who should have insurance access to the brain imaging technology, the two organizations said. People with unexplained, worsening memory loss or confusion, those with possible Alzheimer’s disease who have unusual symptoms and those with progressive dementia that develops before the age of 65 may benefit, they said.

The groups said such brain scans shouldn’t be used for people 65 or older with conventional signs of Alzheimer’s, those without symptoms or those with unconfirmed complaints about memory loss.

People who already meet the criteria for Alzheimer’s disease won’t get additional benefit from the imaging, the groups said.

The goal of screening is to rule out Alzheimer’s or help manage treatment for those who most likely have it, based on the imaging and other tests, Carrillo said.